Résumé
The evolution in the knowledge of tuberculosis' physiopathology allowed not only a better understanding of the immunological factors involved in the disease process, but also the development of new laboratory tests, as well as the establishment of a histological classification that reflects the host's ability to contain the infectious agent. At the same time, the increasing bacilli resistance led to alterations in the basic tuberculosis treatment scheme in 2009. This article critically examines laboratory and histological investigations, treatment regimens for tuberculosis and possible adverse reactions to the most frequently used drugs.
Sujets)
Adolescent , Adulte , Sujet âgé , Enfant , Femelle , Humains , Mâle , Antituberculeux/usage thérapeutique , Tuberculose cutanée/traitement médicamenteux , Tuberculose cutanée/anatomopathologie , Antibiotiques antituberculeux/usage thérapeutique , Granulome , Isoniazide/usage thérapeutique , Mycobacterium tuberculosis , Nécrose , Pyrazinamide/usage thérapeutique , Rifampicine/usage thérapeutique , Sensibilité et spécificitéRésumé
Cutaneous tuberculosis (CTB) is the result of a chronic infection by Mycobacterium tuberculosis, M. ovis and occasionally by the Calmette-Guerin bacillus. The clinical manifestations are variable and depend on the interaction of several factors including the site of infection and the host's immunity. This article revises the current knowledge about this disease's physiopathology and immunology as well as detailing the possible clinical presentations.